Legend Biotech (LEGN) Operating Expenses (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Operating Expenses data on file, last reported at $85.7 million in Q1 2026.

• Quarterly Operating Expenses rose 21.67% year-over-year to $85.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$331.4 million (up 4.5% YoY) and the FY2025 annual result came in at -$550.5 million, changed 0.04% from the prior year.
• Operating Expenses improved to $85.7 million in Q1 2026, from -$138.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $85.7 million in Q1 2026 to a low of -$148.0 million in Q2 2024.
• A 5-year average of -$93.1 million and a median of -$124.0 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses tumbled 117898.15% — and 2025, when it soared 153.0%.
• Tracing LEGN's Operating Expenses over 5 years: stood at -$107.4 million in 2022, then soared by 99.87% to -$134390.0 in 2023, then tumbled by 103032.67% to -$138.6 million in 2024, then climbed by 0.22% to -$138.3 million in 2025, then soared by 161.97% to $85.7 million in 2026.
• The last three Operating Expenses figures came in at $85.7 million (Q1 2026), -$138.3 million (Q4 2025), and -$147.9 million (Q3 2025), per Business Quant data.